Ultomiris is already approved for PNH and aHUS and in late-stage development ... Wilson Therapeutics and Portola and forging an alliance with gene-silencing specialist Dicerna focusing on ...

paroxysmal nocturnal hemoglobinuria, and atypical haemolytic uremic syndrome. The US patent office has said it will review patents on Soliris after Amgen challenged them, according to court ...

Dec. 10, 2024 — In a single IV injection, a gene therapy targeting cBIN1 can reverse the effects of heart failure and restore heart function in a large animal model. The therapy increases the ...

One of the most highly anticipated FDA decisions this month is for Alnylam Pharmaceuticals, which is seeking to expand the ...

A gene regulatory network is a set of genes, or parts of genes, that interact with each other to control a specific cell function. Gene regulatory networks are important in development ...

In part 4 of this 5-part series, panelists discuss gaps in pediatric food allergy care, stressing better diagnosis, education, and management. Advances in pediatric food allergy and anaphylaxis ...

In part 3 of this 5-part series, panelists discuss the recent Neffy approval, oral immunotherapy, and Xolair’s role in allergy management. Traister notes that while intranasal epinephrine offers a ...

After hours: March 14 at 7:29:53 PM EDT Loading Chart for ALNY ...

SAN FRANCISCO — New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly injections already under review by the FDA.

Mar. 10, 2025 — Researchers shed new light on G-quadruplexes, a type of secondary DNA structure that has attracted attention as a potential therapeutic target in ...

Ventricular tachycardia is an abnormally fast heart beat (with three or more consecutive heart beats at least 100 beats per minute) that originates from one of the ventricles in the heart. The ...